美国非酒精性脂肪性肝病的健康和经济负担及其对退伍军人的影响。
Health and Economic Burden of Nonalcoholic Fatty Liver Disease in the United States and Its Impact on Veterans.
作者信息
Shetty Akshay, Syn Wing-Kin
机构信息
was a Fellow, and is an Attending Physician at the division of gastroenterology and hepatology at Medical University of South Carolina in Charleston. Wing-Kin Syn also is the Acting Chief in the section of gastroenterology at Ralph H. Johnson Veterans Affairs Medical Center in Charleston. Akshay Shetty is currently a Transplant Hepatology Fellow in the division of digestive diseases at David Geffen School of Medicine, University of California Los Angeles.
出版信息
Fed Pract. 2019 Jan;36(1):14-19.
Abstract
NAFLD is a leading cause of chronic liver disease and cirrhosis in the US and is associated with metabolic syndrome, type 2 diabetes, cardiovascular disease, and all-cause mortality.
摘要
非酒精性脂肪性肝病是美国慢性肝病和肝硬化的主要病因，与代谢综合征、2型糖尿病、心血管疾病及全因死亡率相关。
相似文献
1
2
Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease.非酒精性脂肪性肝病患者死亡的原因和风险概况。
Clin Mol Hepatol. 2023 Feb;29(Suppl):S43-S57. doi: 10.3350/cmh.2022.0351. Epub 2022 Nov 22.
3
Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis.患有或未患有肝硬化的非酒精性脂肪性肝病医疗保险受益人的住院和门诊资源利用相关变量。
J Clin Gastroenterol. 2017 Mar;51(3):254-260. doi: 10.1097/MCG.0000000000000567.
4
The Epidemiology, Risk Profiling and Diagnostic Challenges of Nonalcoholic Fatty Liver Disease.非酒精性脂肪性肝病的流行病学、风险评估及诊断挑战
Medicines (Basel). 2019 Mar 18;6(1):41. doi: 10.3390/medicines6010041.
5
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.美国和欧洲非酒精性脂肪性肝病的经济和临床负担。
Hepatology. 2016 Nov;64(5):1577-1586. doi: 10.1002/hep.28785. Epub 2016 Sep 26.
6
Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.非酒精性脂肪性肝病的临床流行病学和疾病负担。
World J Gastroenterol. 2017 Dec 21;23(47):8263-8276. doi: 10.3748/wjg.v23.i47.8263.
7
Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030.2017 - 2030年沙特阿拉伯和阿拉伯联合酋长国的非酒精性脂肪性肝病负担
Saudi J Gastroenterol. 2018 Jul-Aug;24(4):211-219. doi: 10.4103/sjg.SJG_122_18.
8
Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration.在退伍军人健康管理局中识别非酒精性脂肪性肝病的肝纤维化程度。
Dig Dis Sci. 2018 Sep;63(9):2259-2266. doi: 10.1007/s10620-018-5123-3. Epub 2018 May 19.
9
Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.美国非酒精性脂肪性肝炎相关肝硬化的患病率：基于国家健康与营养检查调查数据的分析
Am J Gastroenterol. 2017 Apr;112(4):581-587. doi: 10.1038/ajg.2017.5. Epub 2017 Feb 14.
10
Nonalcoholic Fatty Liver Disease: An Emerging Modern-Day Risk Factor for Cardiovascular Disease.非酒精性脂肪性肝病：一种新出现的现代心血管疾病风险因素。
Cureus. 2022 May 30;14(5):e25495. doi: 10.7759/cureus.25495. eCollection 2022 May.
引用本文的文献
1
Innovative Approaches to NAFLD: Exploring the Role of Nicotinamide in Multicellular Microtissue Models of Liver Fibrosis.非酒精性脂肪性肝病的创新方法：探究烟酰胺在肝纤维化多细胞微组织模型中的作用
J Cell Mol Med. 2025 Jun;29(11):e70606. doi: 10.1111/jcmm.70606.
2
Cinnabarinic acid protects against metabolic dysfunction-associated steatohepatitis by activating aryl hydrocarbon receptor-dependent AMPK signaling.朱红酸通过激活芳烃受体依赖性AMPK信号通路预防代谢功能障碍相关脂肪性肝炎。
Am J Physiol Gastrointest Liver Physiol. 2025 Apr 1;328(4):G433-G447. doi: 10.1152/ajpgi.00337.2024. Epub 2025 Mar 10.
3
Bidirectional associations among gallstone disease, non-alcoholic fatty liver disease, kidney stone disease.胆结石病、非酒精性脂肪性肝病、肾结石病之间的双向关联
World J Gastroenterol. 2024 Dec 14;30(46):4914-4928. doi: 10.3748/wjg.v30.i46.4914.
4
Insights from exploring the interrelated dynamics of gallstone disease, non-alcoholic fatty liver disease, and kidney stone disease.探索胆结石病、非酒精性脂肪性肝病和肾结石病相互关联动态的见解。
World J Gastroenterol. 2024 Dec 14;30(46):4977-4982. doi: 10.3748/wjg.v30.i46.4977.
5
Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease.以微生物群为中心的代谢功能障碍相关脂肪性肝病治疗方法
Clin Mol Hepatol. 2025 Feb;31(Suppl):S94-S111. doi: 10.3350/cmh.2024.0811. Epub 2024 Nov 28.
6
Dietary soy protein reverses obesity-induced liver steatosis and alters fecal microbial composition independent of isoflavone level.膳食大豆蛋白可逆转肥胖引起的肝脏脂肪变性，并改变粪便微生物组成，且与异黄酮水平无关。
Front Nutr. 2024 Oct 28;11:1487859. doi: 10.3389/fnut.2024.1487859. eCollection 2024.
7
Role of Hepatic Stellate and Liver Sinusoidal Endothelial Cells in a Human Primary Cell Three-Dimensional Model of Nonalcoholic Steatohepatitis.非酒精性脂肪性肝炎的人源原代细胞三维模型中肝星状细胞和肝窦内皮细胞的作用。
Am J Pathol. 2024 Mar;194(3):353-368. doi: 10.1016/j.ajpath.2023.12.005. Epub 2023 Dec 28.
8
Microalgae-Sustainable Source for Alternative Proteins and Functional Ingredients Promoting Gut and Liver Health.微藻——促进肠道和肝脏健康的替代蛋白质及功能性成分的可持续来源。
Glob Chall. 2023 Apr 25;7(5):2200177. doi: 10.1002/gch2.202200177. eCollection 2023 May.
9
The Impact of Bariatric-Surgery-Induced Weight Loss on Patients Undergoing Liver Transplant: A Focus on Metabolism, Pathophysiological Changes, and Outcome in Obese Patients Suffering NAFLD-Related Cirrhosis.减肥手术引起的体重减轻对接受肝移植患者的影响：聚焦于非酒精性脂肪性肝病相关肝硬化肥胖患者的代谢、病理生理变化及预后
J Clin Med. 2022 Sep 8;11(18):5293. doi: 10.3390/jcm11185293.
10
Cinnabarinic Acid Provides Hepatoprotection Against Nonalcoholic Fatty Liver Disease.肉桂酸对非酒精性脂肪性肝病有肝保护作用。
J Pharmacol Exp Ther. 2022 Oct;383(1):32-43. doi: 10.1124/jpet.122.001301. Epub 2022 Aug 6.
本文引用的文献
1
The Changing Face of Hepatocellular Carcinoma: Forecasting Prevalence of Nonalcoholic Steatohepatitis and Hepatitis C Cirrhosis.肝细胞癌的变化面貌：预测非酒精性脂肪性肝炎和丙型肝炎肝硬化的患病率
J Clin Exp Hepatol. 2019 Jan-Feb;9(1):50-55. doi: 10.1016/j.jceh.2018.02.006. Epub 2018 Feb 16.
2
Impact of DAAs on liver transplantation: Major effects on the evolution of indications and results. An ELITA study based on the ELTR registry.直接抗病毒药物（DAAs）对肝移植的影响：对适应证和结果演变的主要影响。ELITA 研究基于 ELTR 登记处。
J Hepatol. 2018 Oct;69(4):810-817. doi: 10.1016/j.jhep.2018.06.010. Epub 2018 Jun 27.
3
Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030.建立中国、法国、德国、意大利、日本、西班牙、英国和美国 2016-2030 年非酒精性脂肪性肝病疾病负担模型。
J Hepatol. 2018 Oct;69(4):896-904. doi: 10.1016/j.jhep.2018.05.036. Epub 2018 Jun 8.
4
Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data From a Large U.S. Claims Database.非酒精性脂肪性肝病的医疗费用和利用情况：来自美国大型索赔数据库的真实世界数据。
Hepatology. 2018 Dec;68(6):2230-2238. doi: 10.1002/hep.30094. Epub 2018 Sep 20.
5
Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data.美国非酒精性脂肪性肝炎相关肝硬化的患病率：基于国家健康与营养检查调查数据的分析
Am J Gastroenterol. 2017 Apr;112(4):581-587. doi: 10.1038/ajg.2017.5. Epub 2017 Feb 14.
6
Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.等待肝移植的肝硬化或肝衰竭患者中丙型肝炎病毒感染、非酒精性脂肪性肝炎和酒精性肝病患病率的变化。
Gastroenterology. 2017 Apr;152(5):1090-1099.e1. doi: 10.1053/j.gastro.2017.01.003. Epub 2017 Jan 11.
7
Reduction in liver transplant wait-listing in the era of direct-acting antiviral therapy.直接抗病毒治疗时代肝移植等待名单的减少
Hepatology. 2017 Mar;65(3):804-812. doi: 10.1002/hep.28923. Epub 2016 Dec 24.
8
The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe.美国和欧洲非酒精性脂肪性肝病的经济和临床负担。
Hepatology. 2016 Nov;64(5):1577-1586. doi: 10.1002/hep.28785. Epub 2016 Sep 26.
9
Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis.患有或未患有肝硬化的非酒精性脂肪性肝病医疗保险受益人的住院和门诊资源利用相关变量。
J Clin Gastroenterol. 2017 Mar;51(3):254-260. doi: 10.1097/MCG.0000000000000567.
10
Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.全球非酒精性脂肪性肝病流行病学——患病率、发病率和结局的荟萃分析评估。
Hepatology. 2016 Jul;64(1):73-84. doi: 10.1002/hep.28431. Epub 2016 Feb 22.
Zotero 插件